Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
Denosumab, which has been approved for the treatment of osteoporosis since 2010, is a fully humanised monoclonal antibody against a cytokine, receptor activator of nuclear factor kappa B ligand (RANKL), involved in bone resorption. Continued use of denosumab results in a potent and sustained decreas...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Korean Endocrine Society
2022-04-01
|
| Edice: | Endocrinology and Metabolism |
| Témata: | |
| On-line přístup: | http://www.e-enm.org/upload/pdf/enm-2021-1369.pdf |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|